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Summary
Lyme borreliosis is caused by Borrelia burgdorferi sensu
lato infection, which responds well to antibiotic therapy in
the overwhelming majority of cases. However, despite ad-
equate antibiotic treatment some patients report persisting
symptoms which are commonly summarised as post-treat-
ment Lyme disease syndrome (PTLDS). In 2005, the Swiss
Society of Infectious Diseases published a case definition
for PTLDS. We aimed to review the scientific literature
with a special emphasis on the last 10 years, questioning
whether the definitions from 2005 are still valid in the light
of current knowledge. Furthermore, we describe the clinic-
al history of infection with Borrelia burgdorferi sensu lato,
the estimated prevalence of PTLDS, the possible pathogen-
esis of PTLDS, and treatment options with an emphasis on
clinical studies.
In summary, we were unable to find a scientific reason for
modification of the PTLDS definitions published in 2005.
Thus, the diagnostic criteria remain unchanged, namely
documented clinical and laboratory evidence of previous
infection with B. burgdorferi, a completed course of ap-
propriate antibiotic therapy, symptoms including fatigue,
arthralgia, myalgia, cognitive dysfunction or radicular pain
persisting for >6 months, a plausible timely association
between documented B. burgdorferi infection and onset
of symptoms (i.e., persistent or recurrent symptoms that
began within 6 months of completion of a recommended
antibiotic therapy for early or late Lyme borreliosis), and
exclusion of other somatic or psychiatric causes of symp-
toms. The main therapeutic options remain cognitive be-
havioural therapy and low-impact aerobic exercise pro-
grammes. Growing and unequivocal evidence confirms
that prolonged or repeated antibiotic therapy for PTLDS is
not beneficial, but potentially harmful and therefore con-
traindicated.
The Guidelines of the Swiss Society of Infectious Diseases
offer an evidence based, diagnostic and therapeutic frame-
work for physicians caring for patients suffering from pre-
sumptive PTLDS in Switzerland.
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Introduction
Lyme borreliosis is caused by infection with Borrelia bur-
gdorferi sensu lato, which responds well to antibiotic ther-
apy in the overwhelming majority of cases. Nevertheless,
various reports suggest that 2 to 40% of appropriately
treated patients may subsequently suffer from persisting
minor to severe symptoms, including fatigue, musculo-
skeletal or neurocognitive symptoms, lasting for months or
even years [1–9]. The aetiology of such post-Lyme symp-
toms, however, was fiercely debated. In 2005, the Swiss
Society for Infectious Diseases published guidelines for the
diagnosis and treatment of Lyme borreliosis [10–15], in-
cluding a case definition for post-treatment Lyme disease
syndrome (PTLDS) (table 1). The Infectious Diseases So-
ciety of America proposed a case definition for PTLDS in
2006 (table 1) [16].
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Ongoing controversies on whether post-Lyme disease
symptoms reflect a distinct clinical syndrome, how to
define the syndrome, how to distinguish the syndrome from
other unspecific chronic fatigue-like illnesses or chronic
pain disorders, and the growing influence of patient ad-
vocacy groups [17], urged us to review the literature on
PTLDS with a focus on recent data and on current recom-
mendations of European and North American guidelines
(table 2) [16, 18–22].
Case definition of post-treatment
Lyme disease syndrome
PTLDS refers to a pattern of nonspecific symptoms that
persist for more than 6 months after proven and appro-
priately treated Lyme borreliosis, and which are caused
neither by active or persistent B. burgdorferi infection nor
by other diseases. Symptoms include fatigue, neurocognit-
ive deficits, arthralgias or myalgias, without clinically de-
tectable or measurable signs [10–16, 18, 23–25]. For the
diagnosis of PTLDS, a well-documented history of distinct
clinical signs and symptoms fitting the case definitions of
Lyme borreliosis [10–16, 18, 25], laboratory evidence of
a previous infection with B. burgdorferi, and a plausible
chronology of clinical manifestations of Lyme borrelios-
is and subsequent symptoms (i.e., persistent or recurrent
symptoms that began within 6 months of completion of
therapy with a recommended antibiotic for early or late
Lyme borreliosis, and persist for 6 months or longer) are
required. Furthermore, other somatic, psychiatric or beha-
vioural aetiologies for the reported symptoms must metic-
ulously be excluded (table 1). Of note, positive Lyme ser-
ology without previous manifestations of Lyme borreliosis
does not qualify for the diagnosis of PTLDS (table 3).
Strle et al. [26] speculated that post-Lyme symptoms might
be attributed to more than one syndrome, possibly encom-
passing conditions of less severe symptoms such as mal-
aise, fatigue or minor arthralgias lasting for months after
adequate treatment of Lyme Borrelia infection, and more
disabling conditions of severe musculoskeletal pain and in-
Table 1: Swiss and US case definitions of post-treatment Lyme disease syndrome (PTLDS).
Criteria of the Swiss guidelines for PTLDS [10–15] Criteria of the US guidelines for PTLDS [16]
Inclusion criteria
‒ Documented clinical and laboratory evidence for previous Lyme borreliosis
‒ Completed therapy, documented and adequate for the stage
‒ Persisting or recurrent symptoms such as fatigue, arthralgia, myalgia, cognitive
dysfunction or radicular pain, for more than 6 months after antibiotic therapy
‒ A plausible and timely association between documented B. burgdorferi infection
and the onset of PTLDS symptoms, i.e., persistent or recurrent symptoms began
within 6 months of completion of antibiotic therapy, and persist for 6 months or
greater
‒ Objective signs obtained from clinical examination are not required
‒ An adult or child with a documented episode of early or late Lyme disease
fulfilling the case definition of the Centers for Disease Control and Prevention
‒ Treatment with a generally accepted treatment regimen, with resolution or
stabilization of the objective manifestation(s) of Lyme disease
‒ Onset of any of the following subjective symptoms within 6 months of the
diagnosis of Lyme disease and persistence of continuous or relapsing symptoms
for at least a 6 month period after completion of antibiotic therapy:
• Fatigue
• Widespread musculoskeletal pain
• Complaints of cognitive difficulties
• Subjective symptoms are of such severity that, when present, they result in
substantial reduction in previous levels of occupational, educational, social, or
personal activities.
Exclusion criteria
‒ Evidence for an active infection
‒ Concurrent other disease, including active and ongoing rheumatologic,
neurological or psychiatric disease
‒ An active, untreated, well-documented co-infection, such as babesiosis.
‒ The presence of objective abnormalities on physical examination or on
neuropsychologic testing that may explain the patient’s complaints.
‒ A diagnosis of fibromyalgia or chronic fatigue syndrome before the onset of Lyme
disease.
‒ A prolonged history of undiagnosed or unexplained somatic complaints, such as
musculoskeletal pains or fatigue, before the onset of Lyme disease.
‒ A diagnosis of an underlying disease or condition that might explain the patient’s
symptoms.
‒ Laboratory or imaging abnormalities that might suggest an undiagnosed process
distinct from PTLDS
‒ Although testing by either culture or PCR for evidence of Borrelia burgdorferi
infection is not required, should such testing be done by reliable methods, a
positive result would be an exclusion.
Table 2: Post-treatment Lyme disease syndrome in different professional guidelines and position papers.
Country/region, year Society or authors, reference Short version of case definition
Switzerland, 2005 Swiss Society for Infectious Diseases
[10–15]
see table 1
USA, 2006 Infectious Diseases Society of America
(IDSA) [16]
see table 1
Europe, 2010 European Federation of Neurological
Societies (EFNS) [19]
No specific definition of PTLDS is provided. Antibiotic therapy and the treatment trials are being
discussed. Antibiotic treatment is strongly discouraged. The evidence for this recommendation is
rated as level A, the highest rating possible.
Europe, 2011 European Union Concerted Action on
Lyme Borreliosis (EUCALB) [25]
No specific definition of PTLDS is provided. A chapter called “Subjective Long-term Sequelae of Lyme
Borreliosis” describes some features of Post Lyme, emphasizing that the symptoms are not due to
active infection.
United Kingdom, 2011 British Infection Association [21] No specific definition of PTLDS is provided. A chapter entitled “Persistent symptoms following treated
Lyme borreliosis; chronic Lyme disease” discusses PTLDS, referring to a large extent to the IDSA
guidelines.
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capacitating fatigue persisting for years after treated Lyme
borreliosis [22, 27–31].
Clinical scenarios
In table 4 we describe different possible clinical outcomes
of B. burgdorferi infection. When evaluating patients with
presumed PTLDS, the following scenarios need to be con-
sidered in the differential diagnosis:
‒ Patients with manifest Lyme borreliosis, treated or not
treated. This group includes patients with undiagnosed
infection due to B. burgdorferi, with missed diagnosis,
or with correct diagnosis but as yet inadequate antibiot-
ic treatment, i.e., inappropriate choice, wrong dosage,
insufficient duration, or inappropriate route of applica-
tion, or patient's nonadherence to treatment.
‒ Patients who in the past had proven Lyme borreliosis,
were adequately treated and have no active infection.
All of them are microbiologically cured, but some may
suffer from PTLDS.
‒ Patients who never had Lyme borreliosis but who be-
lieve that Borrelia sp. infection is the cause of their
complaints. This group includes misdiagnosed patients
(e.g., multiple sclerosis) or individuals with self-dia-
gnosis who have no clinical or laboratory evidence of
prior infection; patients who experienced adverse ef-
fects of nonindicated treatments for wrongly presumed
Lyme borreliosis; patients with missed other somatic,
psychiatric or behavioural morbidity; patients who
prefer the diagnosis of Lyme borreliosis to other dia-
gnoses; or patients with disease conviction.
Clinical course of early and late
manifestations of Lyme borreliosis,
and post-treatment residual
symptoms
Following antibiotic treatment, resolution of the symptoms
and signs of Lyme borreliosis and residual symptoms vary
depending on the initial clinical manifestations.
In prospective treatment trials of Lyme borreliosis, in
which patients were continuously observed after treatment
of proven infection, it appears plausible to link persisting
symptoms, which were not present before infection, with
B. burgdorferi infection. In contrast, prevalence studies of
fatigue-like symptoms and musculoskeletal pain in Lyme
borreliosis are more difficult to interpret, because approx-
imately 1 year after treatment of Lyme borreliosis the pre-
valence of reported symptoms is often comparable to that
of an uninfected population [32–34].
Erythema migrans
Erythema migrans is the most common manifestation of B.
burgdorferi infection. If treated with antibiotics, skin le-
sions and, if present, systemic symptoms, usually resolve
within 14 days [23]. However, some nonspecific symptoms
may persist for weeks or even months after adequate treat-
ment in the absence of any evidence of persisting infection
Table 3: Minimal diagnostic work up before consideration of post-treatment Lyme disease syndrome.
‒ Complete physical examination including neurological and rheumatological assessment
‒ Past medical history, including clinical and laboratory (Borrelia serology) documentation of prior presumed Lyme borreliosis
‒ Complete blood count
‒ Blood chemistry including electrolytes, kidney and liver function
‒ Thyroid-stimulating hormone
‒ Anti-nuclear antibodies
‒ Chest X ray
‒ Psychiatric consultation
‒ Computed tomography or magnetic resonance imaging of the head in the case of chronic headache and no plausible explanation
‒ In the case of focal signs or symptoms: imaging and histopathological evaluation
‒ In the case of neurological symptoms: CFS examination with Lyme serology (serum and CSF) and CSF/serum index
CSF = cerebrospinal fluid
Table 4: Definitions and outcome of Borrelia burgdorferi infection.
Case
classification of
Lyme
borreliosis
Confirmed: (a) a case with erythema migrans; or (b) a case with at least one late manifestation, as defined in [16, 95] that is laboratory confirmed [96]:
positive culture for B. burgdorferi, or two-tier testing interpreted using established criteria, where positive IgM is sufficient only when ≤30 days from
symptom onset, positive IgG is sufficient at any point during illness; single-tier IgG immunoblot seropositivity using established criteria; CSF antibody
positive for B. burgdorferi corrected with the Reiber-Quotient for intrathecal antibody production.
Asymptomatic
seroconversion
Seroconversion after tick bite without clinical signs of Lyme borreliosis.
Progression of
disease
without
treatment
In North America, progression to monoarthritis in untreated patients (B. burgdorferi sensu stricto) is frequent (around 60% of cases), whereas in Europe
acrodermatitis chronica atrophicans (B. afzelii) and neurological involvement (B. garinii) are more frequent as a result of differences in organ tropism of
different Borrelia strains.
Uncomplicated
course
Infection with B. burgdorferi is diagnosed and treated promptly, and cured.
Delayed cure Infection with B. burgdorferi is diagnosed and treated with delay, resulting in microbiological cure but possibly resulting in protracted clinical symptoms.
Sequelae State-of-the-art treatment of arthritis, acrodermatitis chronica atrophicans or neuroborreliosis results in microbiological cure but not in complete resolution
of symptoms in any case (see section: "Clinical course of Lyme borreliosis, and post-treatment residual symptoms").
Post-treatment
Lyme disease
syndrome
Persistence of fatigue-like symptoms and musculoskeletal pain for more than 6 months despite correct diagnosis and adequate treatment of proven Lyme
borreliosis, and exclusion of other causes of symptoms
Chronic Lyme
borreliosis
No scientific evidence that B. burgdorferi may persist despite adequate therapy. Persistent symptoms after treatment are not caused by active infection.
Thus, chronic Lyme borreliosis after treatment does not exist.
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[23, 32]. These symptoms may include fatigue, malaise,
arthralgia, headache, myalgia, paraesthesia, dizziness,
nausea, insomnia, sleepiness, forgetfulness, concentration
difficulties, irritability, and pain [33]. After erythema mi-
grans, 5.6 to 11% of patients experience persisting symp-
toms 6 months after treatment, depending on the patient
populations assessed [8, 33].
Neuroborreliosis
Neuroborreliosis is the second most important acute or sub-
acute clinical manifestation in Europe [35], mainly caused
by B. garinii. With antibiotic treatment, patients improve
rapidly and substantially [36]. After discontinuation of an-
tibiotics, the clinical manifestations continue to improve,
albeit often protractedly or incompletely: more than half
of patients still experience symptoms after 4 months [36],
and many (range: 23–100%) may continue to suffer from
persisting neurological sequelae [2, 34, 37]. In a recent re-
view, however, the authors conclude that literature on phar-
macological treatments of acute Lyme neuroborreliosis is
scarce and of limited quality and does not allow any recom-
mendations regarding more severe forms such as encephal-
itis [38].
A prospective, randomised trial in Norway comparing in-
travenous ceftriaxone with oral doxycycline in patients
with mostly early neuroborreliosis documented noninferi-
ority of the oral regimen [36]. Of note, only 26 (48%)
patients in the doxycycline group and 16 (33%) in the
ceftriaxone group had complete clinical recovery after 4
months. This observation indicates that despite bacteriolo-
gically successful treatment, more than half of patients may
have persistent signs and symptoms.
Lyme arthritis
Lyme arthritis is a common manifestation of borreliosis in
North America, where up to 50% of affected patients suf-
fer from intermittent episodes of arthritis, 18% experien-
ce arthralgia (independently from arthritis), and 11% de-
velop chronic arthritis. In the USA, 60 to 80% of patients
with untreated erythema migrans will develop joint symp-
toms [39]. In contrast, arthritis occurs less frequently in
Europe [23], but clinical manifestations appear to be sim-
ilar to those described in the USA [40–42]. In surveys in
Germany, between 2 and 5% of patients with Lyme borrel-
iosis developed Lyme arthritis [43, 44]: for example, sur-
veillance data from 2009–2012 of human Lyme borreliosis
from six federal states found arthritis in 2.0% of the noti-
fied 18 894 cases [44]. Lyme arthritis typically responds to
an adequate course of antibiotics [39, 45].
Generalised arthralgias may occur shortly after erythema
migrans (mean: 2 weeks) and never progress to joint ab-
normalities. Frank arthritis develops a mean of 6 months
(range: 4 days to 2 years) after unrecognised or untreated
acute infection, and classically presents as monoarthritis or
oligoarthritis mainly involving the knee (in 96% of cases).
Patients may experience flare-ups of arthritis after treat-
ment [39], and some may benefit from a second treatment
course with antibiotics [16]. However, if arthritis persists
after a second course of appropriate antibiotics, persisting
arthritis is the consequence of an unabated inflammatory
process and not due to persisting bacterial infection. Ap-
proximately 10% of patients may develop the so-called
“antibiotic refractory” late Lyme arthritis [23]. This disease
entity has a defined pathological correlate – persisting pro-
liferative synovitis with a negative borrelial polymerase
chain-reaction (PCR) test. This unabated process is prob-
ably due to immune dysregulation or infection-induced
autoimmunity [46, 47]. Management includes anti-inflam-
matory treatment with nonsteroidal anti-inflammatory
agents, intra-articular corticosteroids, methotrexate, or syn-
ovectomy [23, 46]. Importantly, repeated antibiotic courses
do not improve clinical outcome [16, 46].
Other manifestations of Lyme borreliosis
Lyme carditis is a rare manifestation of acute to subacute
Lyme borreliosis, often presenting with high-grade atri-
oventricular block, which is potentially fatal [48], and
therefore patients should be admitted to hospital for close
monitoring. Temporary pacing may be required. In general,
conduction disturbances resolve within 6 weeks after anti-
biotic treatment [16, 23].
Borrelial lymphocytoma is a rare cutaneous manifestation
reported mainly in Europe and is observed more often in
children than in adults. It responds to antibiotic therapy
within weeks [23].
Acrodermatitis chronica atrophicans, mainly caused by B.
afzelii, is a rare skin manifestation occurring months to
years after infection. It responds well to antibiotic treat-
ment, but may take months to years to improve if treatment
initiation was delayed [49], or may not completely resolve
if treatment was not started before the occurrence of the at-
rophic phase of the disease.
Long-term clinical course of Lyme
borreliosis
Selected studies on the long-term clinical course of Lyme
borreliosis with an emphasis on erythema migrans and
neuroborreliosis are summarised in table 5, which is di-
vided in six sections: (1) randomised controlled treatment
trials; (2) prospective antibiotic treatment trials comparing
outcome with matched, healthy individuals as a comparis-
on group; (3) prospective cohort studies, comparing out-
come with matched, healthy individuals as a control group;
(4) cohort studies without a comparison group; (5) ret-
rospective studies with matched, healthy individuals as a
comparison group; (6) retrospective studies without a com-
parison group.
The best available data were derived from randomised con-
trolled antibiotic treatment trials which show that 5 to 10%
of patients report persisting symptoms after 6 to 12 months.
In contrast, prospective treatment trials also including a
healthy comparison group (without intervention, consisting
of age-matched friends or relatives of patients who were
asked to answer the same questionnaire as patients in the
treatment groups) did not detect any significant differences
in long-term outcome between patients and healthy con-
trols:
‒ A trial assessing different treatment durations for eryth-
ema migrans in 225 patients, and including an addition-
al group of 81 healthy volunteers who had no interven-
tion, did not find any significant differences in outcome
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between patients and healthy controls after 6 months
[33]. The (persisting) symptoms included, among oth-
ers, fatigue (post-Lyme 56.4% vs control 54.3%), mal-
aise (39.6% vs 45.7%), and arthralgias (41.6% vs 42%).
‒ A large treatment trial with a total of 285 European pa-
tients with erythema migrans, and 259 controls did not
find any difference in long-term outcome between pa-
tients who had Lyme borreliosis and individuals who
did not [32]. Six months after treatment, fatigue (post-
Lyme 3.1% vs control 4.7%), arthralgia (3.1% vs
4.7%), headache (0.5% vs 2.5%), and myalgia (2.1% vs
1.7%) did not differ significantly between groups.
Thus, nonspecific symptoms appear frequent in the general
population, and nonspecific symptoms after Lyme borreli-
osis do not appear to be more prevalent in patients than in
control groups. However, the frequency of general symp-
toms in these so-called “healthy control groups” who had
no comprehensive medical evaluation, was indeed surpris-
ingly high, suggesting problematical selection of comparis-
on groups; for example, Stupica et al. reported a frequency
of around 40% [33]. Furthermore, there were 10-fold dif-
ferences in the frequencies of symptoms in control groups
depending on the respective study, suggesting that the pop-
ulation assessed, or the methods used to evaluate the symp-
toms, may influence the prevalence of nonspecific symp-
toms.
Examples of prospective cohort studies include a study on
neuroborreliosis in 177 children which showed that resid-
ual facial palsy (post-Lyme 6% vs control 0%) was more
frequent in children after neuroborreliosis, whereas head-
ache (12% vs 24%) and fatigue (6% vs 20%) were not [35].
In another long-term cohort of 128 patients in the USA
with culture-confirmed Lyme borreliosis, followed up over
a median of 15 years (range: 11–20 years), 14 (10.9%) were
regarded as having PTLDS, of whom 6 (4.7%) still had
PTLDS documented at their last study visit, indicating that
PTLDS may persist for more than a decade. Nevertheless,
none of these patients was considered to be functionally
impaired by their symptoms [50].
Two small retrospective studies including control persons
showed significantly more symptoms persisting in patients
after Lyme disease or initial neuroborreliosis when com-
pared with controls [2, 37].
‒ A retrospective, population-based cohort study showed
a significantly increased frequency of arthralgias,
neurocognitive impairment and myelopathy, in the
follow-up [2].
‒ Another small retrospective investigation of 20 patients
with past neuroborreliosis revealed significantly more
neuropsychological deficits in the long-term course
when compared with healthy controls [37].
In summary, the available data suggest that two types of
persisting symptoms after initial neuroborreliosis need to
be distinguished. First, "focal" and well-defined signs and
symptoms caused by irreversible inflammatory tissue dam-
age, such as facial palsy or myelopathy, usually due to
delayed onset of therapy. Second, “generalised or diffuse”
nonspecific symptoms not attributable to tissue damage, in-
cluding fatigue, generalised pain and myalgia were found
to be of similar frequency when compared with control
groups.
A recently published systematic review of residual symp-
toms after adequate treatment of Lyme neuroborreliosis
[51] showed that the mean prevalence of residual symp-
toms was approximately 28%. Subgroup analyses showed
that studies limited to “probable” or “definite” Lyme
neuroborreliosis cases had a lower prevalence of residual
symptoms than studies including “possible” cases, indicat-
ing the importance of specific case definitions to exclude
false positive findings.
Can Lyme borreliosis become chronic?
Whether PTLDS is a specific disease remains controversial
because of the lack of objective evidence of an ongoing im-
munological or infectious process in patients with correctly
treated Lyme disease. Furthermore, identical symptoms ap-
pear to be equally prevalent in individuals without a his-
tory of Lyme borreliosis [16, 23]. Also, original data on
PTLDS are scarce and heterogeneous, and no standardised,
validated and widely accepted case definition is available.
Moreover, the debate on PTLDS is confused by the discus-
sion on whether Borrelia infection can persist and become
chronic after adequate treatment [52].
Indeed, there is no scientific evidence of chronic Lyme bor-
reliosis be it due to either microbiological failure of ap-
propriate antibiotic treatment, antibiotic resistance [16, 53],
or pathogen persistence after correct treatment [22, 54]. B.
burgdorferi culture results from erythema migrans skin le-
sion biopsies following adequate antibiotic treatment have
been negative in almost all patients, including those with
persisting symptoms after treatment [32, 33]. Furthermore,
there are also no records of a reactivation of hypothetic-
ally latently persisting B. burgdorferi among immunocom-
promised hosts, as can be observed in latent infections due
to intracellularly persisting pathogens.
However, if unrecognised and untreated, Borrelia infection
can cause persisting and increasing symptoms over months.
Among 240 American patients with “chronic Lyme borrel-
iosis”, 19% had active Lyme borreliosis [9], although 60%
had no evidence of Lyme disease at all.
Treatment data on PTLDS
The best available evidence on the natural history of
PTLDS and the effect of antibiotic treatment can be ob-
tained from randomised, controlled, prospective clinical
trials comparing antibiotic treatment with placebo in pa-
tients with persisting symptoms following proven acute
Lyme borreliosis (table 6) [29–31, 55–57].
Klempner et al. included 115 patients in two double-blind
placebo-controlled clinical trials [29]. Patients were eli-
gible if they had a documented clinical history, laboratory
findings of Lyme borreliosis, and documented adequate an-
tibiotic treatment. Symptoms attributed to PTLDS had to
have begun within 6 months after infection and to have per-
sisted for at least 6 months. Patients with negative serology
for borreliosis were included only if an erythema migrans
was clearly documented by an experienced physician. Pa-
tients were randomly assigned in a 1:1 ratio to receive
either antibiotics or placebo. The antibiotic treatment con-
sisted of 1 month of intravenous ceftriaxone followed by
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Table 5: Selected studies on the persistence of symptoms after antibiotic treatment of Lyme borreliosis.
Author Country Study design Initial clinical
manifestations
Follow-up Patients with
persisting
symptoms
n (%)
Comparison
group
n
Comparison
group with
symptoms
n (%)
Remarks
Randomised controlled antibiotic treatment trials of Lyme borreliosis
Nadelman,
1992 [97]
USA RCT of two antibiotics,
cefuroxime and
doxycycline
Early Lyme
disease
1 year 8/86 (9.3) n.a. n.a. No difference between
antibiotics
Strle, 1992 [98] Slovenia RCT of three
antibiotics, penicillin,
azithromycin, and
doxycycline
Erythema
migrans
2 years 4/64 (6.3) n.a. n.a. No difference between
antibiotics
Strle, 1993 [99] Slovenia RCT of two antibiotics,
azithromycin and
doxycycline
Erythema
migrans
1 year 3/107 (2.8) n.a. n.a. No difference between
antibiotics
Luger, 1995
[100]
USA RCT of two antibiotics,
cefuroxime and
doxycycline
Erythema
migrans
1 year 15/232 (6.4) n.a. n.a. No difference between
antibiotics
Luft, 1996
[101]
USA RCT of two antibiotics,
azithromycin and
amoxicillin
Erythema
migrans
6 months 21/217 (9.7) n.a. n.a. Amoxicillin was an
effective therapeutic
agent.
Dattwyler,
1997 [4]
USA RCT of two antibiotics,
intravenous ceftriaxone
and doxycycline
Disseminated
Lyme disease
9 months 6/120 (5.0) n.a. n.a. No difference between
antibiotics
Prospective clinical antibiotic treatment trials of Lyme borreliosis, comparing outcome with matched, healthy individuals as a comparison group
6 months 11/195 (5.6)Cerar, 2010
[32]
Slovenia Prospective RCT of two
antibiotics. Comparison
with matched healthy
comparison group
Erythema
migrans 1 year 7/230 (3.0)
236 individuals
without Lyme
borreliosis
21 (9.4) No difference in
outcome between
patients and
comparison group
6 months 21/197 (10.6)Stupica, 2012
[33]
Slovenia RCT of two antibiotics.
Comparison with
matched healthy
comparison group
Erythema
migrans 1 year 13/177 (7.3)
81 individuals
without Lyme
borreliosis
Number of
symptomatic
controls not
explicitly
stated, only
symptoms are
reported
Comparison group and
patient population with
same frequency of
symptoms after 6
months
Prospective cohort studies of Lyme borreliosis, comparing outcome with matched, healthy individuals as a control group
Skogman,
2008 [34]
Sweden Prospective cohort
study
Children with
neuroborreliosis
6 months 37/177(20.9) 174 Number of
symptomatic
controls not
explicitly
stated, only
symptoms are
reported
Patients: more facial
palsy; comparison
group: more headache
and fatigue
Prospective cohort studies of Lyme borreliosis without a comparison group
Hammers-
Berggren,
1993 [102]
Denmark Prospective cohort
study
Neuroborreliosis 18 months 7/27(26.0) n.a. n.a.
Gerber, 1996
[103]
USA Prospective cohort
study
Lyme disease in
children
25.4 months 0/201 (0) n.a. n.a.
Smith, 2002 [7] USA Prospective cohort
study
Erythema
migrans
2 months 5/118 (4.2) n.a. n.a. Microbiologically
confirmed Lyme
disease
6 months 44/114 (38.6)Berglund, 2002
[104]
Sweden Prospective population-
based survey
Neuroborreliosis
5 years 28/114 (24.6)
n.a. n.a.
Nowakowski,
2003 [105]
USA Prospective cohort
study
Erythema
migrans
≥1 year (mean
5.6 ± 2.6)
8/81 (10) n.a. n.a. Overall excellent clinical
outcome
Ljostad, 2008
[36]
Norway Prospective, clinical trial Neuroborreliosis 4 months 60/102 (58.8) n.a. n.a.
Weitzner, 2015
[50]
USA Prospective study Symptomatic
early Lyme
borreliosis, B.
burgdorferi
positive skin or
blood cultures
15 (11–20)
years
14/128 (10.9) n.a. n.a. 6 (4.7%) with PTLDS at
their last visit
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Table 5: Selected studies on the persistence of symptoms after antibiotic treatment of Lyme borreliosis.
Author Country Study design Initial clinical
manifestations
Follow-up Patients with
persisting
symptoms
n (%)
Comparison
group
n
Comparison
group with
symptoms
n (%)
Remarks
Retrospective studies with matched, healthy individuals as a comparison group
Shadick, 1994
[2]
USA Population-based
retrospective cohort
study
Lyme disease 6.5 years,
range 1–11
years
13/38 (34) 43 Comparison
group had
significantly
fewer
symptoms in
psychometric
evaluation.
Benke, 1995
[37]
Austria Retrospective cohort
study
Lyme
encephalopathy
4.3 years
(average)
20/20 (100) 20 In a statistical
model,
differences
between
groups were
not significant.
All patients performed
worse compared to
healthy comparison
group
Seltzer, 2000
[6]
USA Two-part study
including a community-
based longitudinal
cohort and matched
cohort study
All
manifestations
51 months,
range 15–135
months
13.7–33.5%/
212 patients,
depending on
the symptoms
assessed
14.2–24.1% of
212 patients,
depending on
the symptoms
assessed
Differences
between
controls and
patients were
not significant
in logistic
regression.
The difference between
patients and healthy
comparison group were
overall not significant,
assessing a total of 18
different non-specific
symptoms and 2
standardised
neuropsychological
tests
Vazquez, 2003
[6]
USA Retrospective, cross-
sectional study with
matched comparison
group
Children with
Lyme disease
8 years, range
7–61 months
9/34 (26.4) Substantial
number of
nonspecific
symptoms in
the comparison
group
The difference between
patients and healthy
comparison group was
overall not significant,
including a total of 20
different nonspecific
symptoms
Retrospective studies without a comparison group
Hammers-
Berggren,
1994 [106]
Denmark Retrospective study Erythema
migrans and
neuroborreliosis
2.5 years,
median (3
month to 10
years)
23/91 (25) n.a. n.a. 5 patients (5%)
incapacitated
Hammers-
Berggren,
1994 [107]
Denmark Undefined Lyme arthritis
and
acrodermatitis
chronica
atrophicans
6 months to 5
years
9/41(22) n.a. n.a.
Dersch, 2015
[51]
Various Meta-analysis Neuroborreliosis 7 days to 20
years
28% (95%
confidence
interval:
23–34%)
n.a. n.a. Prevalence of residual
symptoms significantly
higher in studies using
the “possible” case
definition (compared
with “probable”/
“definite”)
n.a. = not applicable; PTLDS = post-treatment Lyme disease syndrome; RCT = randomised controlled trial
2 months of oral doxycycline; clinical response rates were
documented after 3 months. The overall status improved in
roughly one third of patients, remained unchanged in an-
other one third, and deteriorated in one third of patients,
and did not differ between the intervention and the placebo
group.
Krupp et al. [30] included 55 patients with fatigue as key
feature of the disease. Remarkably, the overwhelming ma-
jority of screened patients (512 individuals) were excluded
because they lacked documentation of prior infection with
Borrelia sp. Patients were randomised to intravenous
ceftriaxone or placebo for 1 month. After 6 months, 69% of
patients in the ceftriaxone arm reported improvement of fa-
tigue as opposed to 23% in the placebo arm (p <0.01). Re-
markably, however, neither improvement in mental speed
nor other measures from the neuropsychological test bat-
tery showed any significant difference between the groups.
This is contradictory, since fatigue is in general highly
correlated with other neuropsychological measures, such
as mental speed. Given the very low number of actually
treated patients and the multitude of different measure-
ments, multiple testing may be a problem and is very likely
the explanation for an isolated significant measurement.
Moreover, masking was most probably compromised in
this study. Thus, despite a single significant measurement,
the authors concluded that repeated courses of antibiotics
for PTLDS are not indicated.
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Fallon et al. [31] included 37 patients in a prospective trial.
The authors had a significant recruitment problem. Out
of 3368 “clinic contacts”, 1828 had no documented past
infection with B. burgdorferi. The other 1503 had either
received insufficient antibiotic treatment, were not suffi-
ciently impaired or met other exclusion criteria. Eventu-
ally, 23 patients were randomised to receive intravenous
antibiotic treatment for 10 weeks; 14 patients were given
intravenous placebo. Additionally, 18 healthy individuals
were recruited as “control group”. Cognitive improvement
between baseline and week 12 in the drug-treated patients
was better than in the healthy controls (p <0.01) and not
significantly better than in the placebo-treated patients (p
= 0.053), despite being referred to as significant in the pa-
per. Given the low number of patients, the multitude of
parameters tested, the highly selected patient population
and, last but not least, the absence of statistical significance
between the groups, these findings do not support extended
antibiotic treatment for PTLDS.
A first double-blind, randomised clinical trial in Europe has
recently been completed in the Netherlands. It compared 12
weeks of treatment with either doxycycline, clarithromy-
cin plus hydroxychloroquine or placebo for patients with
persistent symptoms after documented B. burgdorferi in-
fection and an initial 2-week intravenous ceftriaxone treat-
ment of all study participants [56]. Results of this study
suggest that the physical component summary score im-
proved significantly over time in all active treatment
groups but that long-term antibiotic therapy was not asso-
ciated with improved quality of life (p = 0.35). Importantly,
four serious adverse events were thought to be related to
drug use [57].
In summary, the data from these five randomised controlled
trials suggest the following conclusions. First, between 20
and 30% of patients with PTLDS appear to improve over
time with or without repeated antibiotic treatment. Second,
out of 4955 screened patients in the trials of Klempner [29]
and Fallon [31], 1963 (39.5%) were excluded because of
the absence of documented Lyme borreliosis. Thus, a very
large proportion of patients who attributed their symptoms
to PTLDS had no evidence of Lyme borreliosis in the past.
As pointed out in a thoughtful review by Klempner et al.
[55], the trials had a total recruitment time of 123 months.
Despite this lengthy total recruitment period, the investig-
ators were able to include only 221 patients [55]. Finally,
the results from the USA have now also been confirmed in
European patients infected with European borrelial species
[56, 57]. Thus, patient advocacy groups appear to consist-
ently overstate the burden of disease attributed to PTLDS
[58–60].
Possible pathogenesis of PTLDS
Pathogenic mechanisms that would lead to post-Lyme dis-
ease symptoms have not been identified so far. Possible
mechanisms other than active infection (which is very un-
likely), especially immune system abnormalities or
infection-induced autoimmunity, have been suggested. Re-
cently, Strle et al. [26] reported that in European patients
with erythema migrans, mostly due to B. afzelii, high type
1 T-cell-associated CXCL9 and CXCL10 chemokine re-
sponses correlated with more effective immune-mediated
spirochaetal killing, whereas high type 17 helper-T-cell-as-
sociated cytokines and interleukin 23-associated immune
responses correlated with post-Lyme symptoms. Persisting
symptoms in this cohort included arthralgias, headache and
fatigue, which were not incapacitating and usually resolved
within months after antibiotic therapy. However, concerns
about the statistical interpretation of such immunological
findings due to low statistical power have been raised [61].
Controversial results were reported on the association
between humoral immune response to endothelial cell
growth factor and PTLDS [47, 62]. Other potential aeti-
ologies of PTLDS include antineural antibodies, bacterial
debris and tissue destruction [63]. Chronic pain syndromes,
fatigue or neurocognitive deficits were also considered to
be a consequence of a central sensitisation syndrome that
may be induced by infectious or noninfectious stimuli [64].
Table 6: Summary of randomised controlled trials on antibiotic treatment of post-treatment Lyme disease syndrome.
Number of patients OutcomeStudy, reference,
country
Inclusion criteria Baseline characteristics Observation
time Intervention Placebo Intervention Placebo
Klempner et al. (2
studies) [29], USA
Post-Lyme disease with
physical and mental
symptoms
Erythema migrans as initial
presentation 77%; arthralgia
92%; fatigue 88%;
neurocognitive symptoms
65%
3 months 57 58 23 (40%)
improvement, 16
(28%) unchanged, 18
(32%) worse
21 (36%)
improvement, 17
(29%) unchanged,
20 (34%) worse
Krupp et al. [30],
USA
Post-Lyme disease with a
focus on fatigue
Erythema migrans as initial
presentation, 32.6%; lifetime
history of psychiatric
disorder, 63.5%
6 months 28 27 18/28 (64%)
improvement*
5/27 (18.4%)
improvement
Fallon et al. [31],
USA
Post-Lyme disease
syndrome
Erythema migrans as initial
presentation, 54%;
arthralgia, 100%; sensory
abnormality, 100%
1 year 23 14 Significant
improvement after 24
weeks
Significant
improvement after
24 weeks
Berende et al. [56,
57], the
Netherlands
Persistent symptoms
attributed to Lyme
borreliosis
Pain, sensory or cognitive
disturbances
1 year 172 (two
different
treatment
arms)
86 Significant
improvement, not
different between
treatment arms
Significant
improvement, not
different from
antibiotic treatment
* Despite a significantly better outcome in the treatment arm, this difference is not regarded as clinically relevant. Please refer to the text for further discussion of this
matter.
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Psychological or psychiatric
premorbidity and PTLDS
Psychiatric comorbidity is frequent in many somatic ill-
nesses. Psychogenic comorbidity is common because hav-
ing an acute or chronic medical condition that restricts
one's physical or social functions is depressing or anxiety-
provoking, also among resilient individuals without any
premorbid factors. In case of PTLDS, the debate rages as to
whether PTLDS is a consequence of the patients’ percep-
tions of the widely dispersed belief of the potentially most
severe sequelae of Lyme borreliosis, whether premorbid
psychological factors play an aetiological role in PTLDS,
or whether PTLDS may represent a specific or nonspecific
neurobehavioural response to illness [9, 65]. These discus-
sions leave many of the patients frustrated and feeling stig-
matised [66].
Among patients referred to Lyme borreliosis specialty clin-
ics, many suffered from depression and somatic diseases
other than Lyme borreliosis. In 209 patients from the Yale
University Lyme Disease Clinic, 42% reported symptoms
of depression, which in 16% was thought to represent
primary depression [67]. This number is in line with a
more recent investigation by Hassett et al. showing that
over 45% of PTLDS patients had a major depressive epis-
ode [9]. Differentiating between psychiatric disorders and
PLTDS remains challenging [9, 68, 69].
A limited number of studies exploring whether psychiatric
comorbidity and PTLDS are causally related yielded con-
tradictory results. Gaudino et al. reported that 26% of
PTLDS patients had a psychiatric diagnosis before the on-
set of PTLDS [70]. In contrast, Hassett et al. were unable to
detect an association between baseline psychiatric comor-
bidity and symptom persistence after treatment for proven
Lyme borreliosis [9]. Based on their own prospective ob-
servations of patients with recent proven infections, Hassett
et al. concluded that 13 to 32% had ongoing post-Lyme
symptoms: these symptoms, however, were not primarily
related to a psychiatric disorder but rather appeared to be
the consequence of a complex interplay between biologic-
al, psychological and social factors [9, 71, 72]. Subjective
symptoms had no objective correlate in most cases. In par-
ticular, in the majority of the cases, physical and neurocog-
nitive examinations were unrevealing and without evidence
of ongoing inflammation. Although not causal, psycholo-
gical factors, including high negative affect and low posit-
ive affect – all psychological risk factors contributing to the
general experience of psychological stress – appear to con-
tribute to behavioural manifestations of PTLDS, and im-
pact on the patient’s subjective experience of illness [71].
Role of tick-borne co-infections and
PTLDS
After a tick bite, co-infections may occur with pathogens
such as tick borne-encephalitis virus, Anaplasma phagocyt-
ophilum, Babesia microti or other pathogens, and need – if
present – specific antimicrobial treatment. A causative re-
lationship of co-infections to PTLDS has not been estab-
lished [73].
Differences and similarities between
chronic fatigue, fibromyalgia and
PTLDS
Many patients complaining about increased fatigue or gen-
eralised pain associate their condition with a preceding in-
fection [74, 75]. Symptoms of PTLDS may have an aetiolo-
gical and phenomenological overlap with chronic fatigue
syndrome, fibromyalgia and other chronic pain syndromes.
As shown in table 7, the diagnostic criteria of chronic
fatigue and fibromyalgia do substantially overlap with
PTLDS, and the clinical differentiation between fibromy-
algia, chronic fatigue and PTLDS may, by definition, be
blurred. However, the diagnosis of PTLDS requires a pre-
viously documented infection with B. burgdorferi and a
plausible association between Lyme borreliosis and the be-
ginning of persisting symptoms that were not present be-
fore the onset of B. burgdorferi infection.
Among the diseases under discussion, the onset of fibromy-
algia was found to be subsequent to Lyme borreliosis [27],
and Borrelia spp. infection has been implicated as the trig-
ger for chronic fatigue as well [28]. Indeed, the temporal
relationship between Lyme borreliosis and fibromyalgia
may cause a diagnostic dilemma. This can easily be
demonstrated in a study which aimed to systematically as-
sess the development of fibromyalgia after Lyme borrelios-
is [28]. Out of 287 patients with confirmed Lyme borrel-
iosis, 22 (8%) developed fibromyalgia, of whom 15 (5%)
participated in the study; 14 patients had erythema mi-
grans, 7 had CNS involvement, 1 patient had carditis and
6 had signs of late borreliosis. The symptoms of fibromy-
algia included, among others, widespread joint and muscle
pain, fatigue and sleep disturbances. None of the patients
had these symptoms before documented Lyme borreliosis.
Antibiotic treatment did not influence the clinical course.
If the diagnostic criteria for PTLDS were applied (which
were introduced only years after publication of this paper),
all these patients would have fulfilled these diagnostic cri-
teria and would have been diagnosed accordingly.
State of evidence for the existence of
PTLDS
Data from prospective observational studies of previously
healthy persons with Lyme borreliosis, as summarised in
tables 5 and 6, and clinical experience suggest that there are
patients who are essentially free of symptoms until they are
infected with B. burgdorferi. After treatment, these patients
initially show an adequate clinical response with resolution
of clinical signs and symptoms, such as erythema migrans
or other measurable signs. However, a small percentage of
patients start to report fatigue, lack of concentration, mus-
culoskeletal pain or other nonspecific symptoms. Despite
comprehensive diagnostic evaluation, no other reasons for
these symptoms can be identified, and there is no under-
lying premorbid or current psychopathology. The clinical
course with resolving “acute” symptoms being replaced by
nonspecific symptoms, the timely association of acute in-
fection and persisting symptoms, serology and the lack of
any other cause match the case definition of PTLDS.
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Psychological factors have been suggested to play a role in
the aetiology of PTLDS [71]. Indeed, Solomon et al. de-
scribed a clear association between previous psychologic-
al trauma and chronic physical symptoms, such as PTLDS
[65]. This observation leads to the hypothesis that a predis-
posing psychological condition may facilitate the develop-
ment of PTLDS. Regarding the persistence of symptoms,
Hassett et al. showed that functional status and lower posit-
ive affect were predictive of persistence of symptoms [71].
Unexpectedly, the functional status after Lyme borrelios-
is was not related to the functional status at baseline, sug-
gesting that the severity of symptoms does not predict their
persistence. The observation that positive affect influences
clinical outcome has been described for other diseases such
as the common cold [76].
Whether PTLDS is pathophysiologically different from
other post-infectious syndromes remains unclear [77]. The
aetiology notwithstanding, the clearly defined PTLDS,
with an unambiguous clinical course and serology, is sep-
arate from post-Lyme sequelae with measurable or observ-
able signs, such as persisting facial palsy, or other irrevers-
ible central or peripheral post-Lyme neural damage.
“Post hoc ergo propter hoc”
In our experience, the majority of patients with presumed
post-Lyme symptoms do not fulfil the diagnostic criteria of
PTLDS. This notion is supported by observations that more
than half of patients recruited in randomised controlled tri-
als of PTLDS had to be excluded because they failed to ful-
fil the diagnostic criteria [31]. Apparently, many patients
wrongly attributed their present symptoms to a possible in-
fection in the distant past, or linked their symptoms to a
positive serology (“cum hoc ergo propter hoc”). There is
research focusing on psychological and societal circum-
stances, “the contaminated milieu phenomenon”, as sug-
gested earlier [78–80], meaning that unscientific societal
concepts or contexts of health and disease, errors in judg-
ment by both clinicians and patients, the influence of mis-
leading media reports, misinformation on the Internet, or
self-serving support groups, bring patients to neglect any
objective findings, such as lack of laboratory evidence for
borrelial infection [81–84]. Also, it has been noted that in-
dividuals in a society that spends more on healthcare are
more likely to consider themselves as sick [85].
Furthermore, individual vulnerability may influence the
course of disease, as there is a strong link between a history
of psychological trauma and development of chronic phys-
ical symptoms [65]. Indeed, psychiatric comorbidity was
diagnosed in up to 48% of patients who consider them-
selves as having “chronic Lyme disease” [9]. Last but not
least, misconceptions of some healthcare professionals
contribute to iatropathogenesis of “chronic” Lyme borreli-
osis, by supporting unscientific views – often with substan-
tial financial interests – about Lyme disease [86].
Treatment of PTLDS
Many treatment modalities have been propagated; most of
them with no or little scientific evidence – and no proven
effect. Among these, neither long-term, "aggressive" high-
dose antibiotic combinations, cycling of different antibiotic
regimens, nor hyperbaric oxygen, immunomodulators or
psychotropic medication have been beneficial [28, 71, 87,
88], although medication for reducing pain or coexistent
mood disorders may be tried.
In particular, there are no data suggesting that prolonged
antibiotic retreatment after appropriate initial therapy of
Lyme borreliosis has any benefit [55]. Claims for a “re-
appraisal” of the concept are scientifically not valid [55,
89, 90]. In contrast, there are reports of deaths [91, 92] and
substantial morbidity [93] associated with antibiotic ther-
apy for unsubstantiated Lyme borreliosis. Finally, there is
no evidence for specific treatment for PTLDS.
Table 7: Definitions of chronic fatigue syndrome and fibromyalgia.
Case definition of CFS from US Centers for Disease Control and
Prevention [108]
Fibromyalgia diagnostic criteria [108]
Characterised by persistent or relapsing unexplained chronic fatigue A patient fulfils the diagnostic criteria for fibromyalgia if the following 3 conditions are met:
• Fatigue lasts for at least 6 months
• Fatigue is of new or definite onset
• Fatigue is not the result of an organic disease or of continuing exertion
• Fatigue is not alleviated by rest
• Fatigue results in a substantial reduction in previous occupational,
educational, social and personal activities
plus
• Four or more of the following symptoms, concurrently present for 6 months:
– impaired memory or concentration
– sore throat
– tender cervical or axillary lymph nodes
– muscle pain
– pain in several joints
– new headaches
– unrefreshing sleep
– or malaise after exertion
• Widespread pain index (WPI) ≥7 and symptom severity (SS) scale score ≥5 or WPI
3–6 and SS scale score ≥9
• Symptoms (fatigue, waking unrefreshed, cognitive symptoms) have been present at
a similar level for at least 3 months
• The patient does not have a disorder that would otherwise explain the pain
Exclusion criteria Exclusion criteria
• Medical condition explaining fatigue
• Major depressive disorder (psychotic features) or bipolar disorder
• Schizophrenia, dementia or delusional disorder
• Anorexia nervosa, bulimia nervosa
• Alcohol or substance abuse
• Severe obesity
• Exclusion of all potentially relevant somatic diseases and psychiatric diseases
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Given the substantial overlap of symptoms between chron-
ic fatigue syndrome, fibromyalgia, chronic fatigue-like
syndromes and PTLDS, and based on randomised con-
trolled trials on patients with chronic fatigue-like symp-
toms, treatment recommendations for PTLDS mainly in-
clude nonpharmacological approaches: counselling, regu-
lar low-impact aerobic exercise programmes, and cognitive
behavioural therapy [28, 87]. A corresponding concept,
ExPRESS (E stands for exercise; P stands for psychiatric
comorbidity; R stands for regaining function with emphasis
on realistic goals and regular activity; E stands for educa-
tion; S for sleep; and the final S for stress and the need to
manage and reduce it), has been introduced by Hassett and
Gevirtz for the treatment of fibromyalgia, but might also be
a promising approach for the treatment of PTLDS [94].
Conclusions
The case definitions of PTLDS by the Swiss Society for In-
fectious Diseases, published in 2005, and by the Infectious
Diseases Society of America, published in 2006, guide
clinicians and health insureres in the evaluation and treat-
ment of post-Lyme disease symptoms (table 1). We found
no further data, particularly no prospective controlled stud-
ies on Lyme borreliosis, which may change these decade-
old case definitions. For the diagnosis of PTLDS, a set
of fact-based diagnostic criteria has to be fulfilled. Im-
portantly, positive Lyme serology without previous defined
clinical manifestations of Lyme borreliosis does not qualify
for the diagnosis of PTLDS, given the high prevalence of
asymptomatic seropositivity in populations living in en-
demic areas.
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